Risk Management for Radiation-Induced ... - Research NCKU

... for Radiation-Induced Cardiovascular Disease (RICVD): The 2022 Consensus Statement of the Taiwan Society for Therapeutic Radiology and Oncology (TASTRO) ... 跳至主導覽 跳至搜尋 跳過主要內容 RiskManagementforRadiation-InducedCardiovascularDisease(RICVD):The2022ConsensusStatementoftheTaiwanSocietyforTherapeuticRadiologyandOncology(TASTRO)andTaiwanSocietyofCardiology(TSOC) TASTRO-TSOCCardio-OncologyTaskForce 內科學科腫瘤科臨床醫學研究所 研究成果:Reviewarticle›同行評審 1 引文 斯高帕斯（Scopus） 總覽 指紋 摘要 Advancesincancermanagementhavesignificantlyimprovedsurvivalinpatientswithcancers.Cardiovascularcomplicationsofcancertreatmentarebecomingsignificantcompetingcausesofdeathinthesepatients.Radiotherapyisanindispensablecomponentofcancertreatment,andirradiationoftheheartandvasculatureduringcancerradiotherapyisnowrecognizedasanewriskfactorforcardiovasculardiseases.Itisimportanttoinvolvemultidisciplinaryexpertiseandprovidepracticalrecommendationstopromoteawareness,recognizerisks,andprovideadequateinterventionswithoutjeopardizingcancercontrol.Inthisconsensuspaper,expertsfromtheTaiwanSocietyforTherapeuticRadiologyandOncologyandTaiwanSocietyofCardiologyprovideafocusedupdateontheclinicalpracticeforriskstratificationandmanagementofradiation-inducedcardiovasculardisease(RICVD).WebelievethatimplementingRICVDcareunderacollaborativecardio-oncologyprogramwillsignificantlyimprovecancertreatmentoutcomesandwillfacilitatehighqualityclinicalinvestigations. 原文English期刊ActaCardiologicaSinica卷38發行號1DOIshttps://doi.org/10.6515/ACS.202201_38(1).20211122A出版狀態Published-20221月 AllScienceJournalClassification(ASJC)codes心臟病學與心血管醫學 存取文件 10.6515/ACS.202201_38(1).20211122A 其它文件與鏈接 LinktopublicationinScopusLinktocitationlistinScopus RiskManagement Medicine&LifeSciences 90% Cardiology Medicine&LifeSciences 82% Radiation Medicine&LifeSciences 62% CardiovascularDiseases Medicine&LifeSciences 59% Neoplasms Medicine&LifeSciences 26% Radiotherapy Medicine&LifeSciences 16% CauseofDeath Medicine&LifeSciences 9% Heart Medicine&LifeSciences 7% 引用此 APA Author BIBTEX Harvard Standard RIS Vancouver TASTRO-TSOCCardio-OncologyTaskForce(2022).RiskManagementforRadiation-InducedCardiovascularDisease(RICVD):The2022ConsensusStatementoftheTaiwanSocietyforTherapeuticRadiologyandOncology(TASTRO)andTaiwanSocietyofCardiology(TSOC).ActaCardiologicaSinica,38(1).https://doi.org/10.6515/ACS.202201_38(1).20211122A TASTRO-TSOCCardio-OncologyTaskForce./RiskManagementforRadiation-InducedCardiovascularDisease(RICVD):The2022ConsensusStatementoftheTaiwanSocietyforTherapeuticRadiologyandOncology(TASTRO)andTaiwanSocietyofCardiology(TSOC).於:ActaCardiologicaSinica.2022;卷38,編號1. @article{1dc1f4bd33ff485d8398d17bba9ba965,title="RiskManagementforRadiation-InducedCardiovascularDisease(RICVD):The2022ConsensusStatementoftheTaiwanSocietyforTherapeuticRadiologyandOncology(TASTRO)andTaiwanSocietyofCardiology(TSOC)",abstract="Advancesincancermanagementhavesignificantlyimprovedsurvivalinpatientswithcancers.Cardiovascularcomplicationsofcancertreatmentarebecomingsignificantcompetingcausesofdeathinthesepatients.Radiotherapyisanindispensablecomponentofcancertreatment,andirradiationoftheheartandvasculatureduringcancerradiotherapyisnowrecognizedasanewriskfactorforcardiovasculardiseases.Itisimportanttoinvolvemultidisciplinaryexpertiseandprovidepracticalrecommendationstopromoteawareness,recognizerisks,andprovideadequateinterventionswithoutjeopardizingcancercontrol.Inthisconsensuspaper,expertsfromtheTaiwanSocietyforTherapeuticRadiologyandOncologyandTaiwanSocietyofCardiologyprovideafocusedupdateontheclinicalpracticeforriskstratificationandmanagementofradiation-inducedcardiovasculardisease(RICVD).WebelievethatimplementingRICVDcareunderacollaborativecardio-oncologyprogramwillsignificantlyimprovecancertreatmentoutcomesandwillfacilitatehighqualityclinicalinvestigations.",author="{TASTRO-TSOCCardio-OncologyTaskForce}andLu,{LongSheng}andWu,{YenWen}andChang,{JosephTungChieh}andChang,{WeiTing}andChao,{TingHsing}andChen,{HelenHaiWen}andChen,{YuJen}andCheng,{KaiHung}andHsu,{WenLin}andHung,{ChungLieh}andKuo,{SungHsin}andLiang,{JiAn}andLin,{HungJu}andLiu,{PingYen}andLiu,{WenShan}andLiu,{YenWen}andShueng,{PeiWei}andWang,{ChaoYung}andHou,{CharlesJiaYin}andChiou,{JengFong}",note="FundingInformation:ThetaskforcethanksupportfromTASTRO,TSOC,andtheaffiliatedhospitals.Theauthorsarelistedinalphabeticorderexceptforthefirstauthorsandcorrespondingauthors.PublisherCopyright:{\textcopyright}2022,RepublicofChinaSocietyofCardiology.Allrightsreserved.",year="2022",month=jan,doi="10.6515/ACS.202201_38(1).20211122A",language="English",volume="38",journal="ActaCardiologicaSinica",issn="1011-6842",publisher="RepublicofChinaSocietyofCardiology",number="1",} TASTRO-TSOCCardio-OncologyTaskForce2022,'RiskManagementforRadiation-InducedCardiovascularDisease(RICVD):The2022ConsensusStatementoftheTaiwanSocietyforTherapeuticRadiologyandOncology(TASTRO)andTaiwanSocietyofCardiology(TSOC)',ActaCardiologicaSinica,卷38,編號1.https://doi.org/10.6515/ACS.202201_38(1).20211122A RiskManagementforRadiation-InducedCardiovascularDisease(RICVD):The2022ConsensusStatementoftheTaiwanSocietyforTherapeuticRadiologyandOncology(TASTRO)andTaiwanSocietyofCardiology(TSOC)./TASTRO-TSOCCardio-OncologyTaskForce.於:ActaCardiologicaSinica,卷38,編號1,01.2022.研究成果:Reviewarticle›同行評審 TY-JOURT1-RiskManagementforRadiation-InducedCardiovascularDisease(RICVD)T2-The2022ConsensusStatementoftheTaiwanSocietyforTherapeuticRadiologyandOncology(TASTRO)andTaiwanSocietyofCardiology(TSOC)AU-TASTRO-TSOCCardio-OncologyTaskForceAU-Lu,LongShengAU-Wu,YenWenAU-Chang,JosephTungChiehAU-Chang,WeiTingAU-Chao,TingHsingAU-Chen,HelenHaiWenAU-Chen,YuJenAU-Cheng,KaiHungAU-Hsu,WenLinAU-Hung,ChungLiehAU-Kuo,SungHsinAU-Liang,JiAnAU-Lin,HungJuAU-Liu,PingYenAU-Liu,WenShanAU-Liu,YenWenAU-Shueng,PeiWeiAU-Wang,ChaoYungAU-Hou,CharlesJiaYinAU-Chiou,JengFongN1-FundingInformation: ThetaskforcethanksupportfromTASTRO,TSOC,andtheaffiliatedhospitals.Theauthorsarelistedinalphabeticorderexceptforthefirstauthorsandcorrespondingauthors. PublisherCopyright: ©2022,RepublicofChinaSocietyofCardiology.Allrightsreserved.PY-2022/1Y1-2022/1N2-Advancesincancermanagementhavesignificantlyimprovedsurvivalinpatientswithcancers.Cardiovascularcomplicationsofcancertreatmentarebecomingsignificantcompetingcausesofdeathinthesepatients.Radiotherapyisanindispensablecomponentofcancertreatment,andirradiationoftheheartandvasculatureduringcancerradiotherapyisnowrecognizedasanewriskfactorforcardiovasculardiseases.Itisimportanttoinvolvemultidisciplinaryexpertiseandprovidepracticalrecommendationstopromoteawareness,recognizerisks,andprovideadequateinterventionswithoutjeopardizingcancercontrol.Inthisconsensuspaper,expertsfromtheTaiwanSocietyforTherapeuticRadiologyandOncologyandTaiwanSocietyofCardiologyprovideafocusedupdateontheclinicalpracticeforriskstratificationandmanagementofradiation-inducedcardiovasculardisease(RICVD).WebelievethatimplementingRICVDcareunderacollaborativecardio-oncologyprogramwillsignificantlyimprovecancertreatmentoutcomesandwillfacilitatehighqualityclinicalinvestigations.AB-Advancesincancermanagementhavesignificantlyimprovedsurvivalinpatientswithcancers.Cardiovascularcomplicationsofcancertreatmentarebecomingsignificantcompetingcausesofdeathinthesepatients.Radiotherapyisanindispensablecomponentofcancertreatment,andirradiationoftheheartandvasculatureduringcancerradiotherapyisnowrecognizedasanewriskfactorforcardiovasculardiseases.Itisimportanttoinvolvemultidisciplinaryexpertiseandprovidepracticalrecommendationstopromoteawareness,recognizerisks,andprovideadequateinterventionswithoutjeopardizingcancercontrol.Inthisconsensuspaper,expertsfromtheTaiwanSocietyforTherapeuticRadiologyandOncologyandTaiwanSocietyofCardiologyprovideafocusedupdateontheclinicalpracticeforriskstratificationandmanagementofradiation-inducedcardiovasculardisease(RICVD).WebelievethatimplementingRICVDcareunderacollaborativecardio-oncologyprogramwillsignificantlyimprovecancertreatmentoutcomesandwillfacilitatehighqualityclinicalinvestigations.UR-http://www.scopus.com/inward/record.url?scp=85125649158&partnerID=8YFLogxKUR-http://www.scopus.com/inward/citedby.url?scp=85125649158&partnerID=8YFLogxKU2-10.6515/ACS.202201_38(1).20211122ADO-10.6515/ACS.202201_38(1).20211122AM3-ReviewarticleAN-SCOPUS:85125649158VL-38JO-ActaCardiologicaSinicaJF-ActaCardiologicaSinicaSN-1011-6842IS-1ER- TASTRO-TSOCCardio-OncologyTaskForce.RiskManagementforRadiation-InducedCardiovascularDisease(RICVD):The2022ConsensusStatementoftheTaiwanSocietyforTherapeuticRadiologyandOncology(TASTRO)andTaiwanSocietyofCardiology(TSOC).ActaCardiologicaSinica.20221月;38(1).https://doi.org/10.6515/ACS.202201_38(1).20211122A